Literature DB >> 28490424

Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.

Xin-Xing Gu1, Stanley A Plotkin2, Kathryn M Edwards3, Alessandro Sette4, Kingston H G Mills5, Ofer Levy6,7, Andrea J Sant8, Annie Mo9, William Alexander9, Kristina T Lu9, Christopher E Taylor9.   

Abstract

Since the middle of the 20th century, vaccines have made a significant public health impact by controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents that have a complex life cycle and antigenic variation remains a key challenge. Novel strategies to characterize the short- and long-term immune responses to vaccines and to induce immune responses that mimic natural infection have recently emerged. New technologies and approaches in vaccinology, such as adjuvants, delivery systems, and antigen formulations, have the potential to elicit more durable protection and fewer adverse reactions; together with in vitro systems, these technologies have the capacity to model and accelerate vaccine development. The National Institute of Allergy and Infectious Diseases (NIAID) held a workshop on 19 September 2016 that focused on waning immunity to selected vaccines (for Bordetella pertussis, Salmonella enterica serovar Typhi, Neisseria meningitidis, influenza, mumps, and malaria), with an emphasis on identifying knowledge gaps, future research needs, and how this information can inform development of more effective vaccines for infectious diseases.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Bordetella pertussis; Neisseria meningitidis; Salmonella; adjuvants; immunity; influenza; malaria; mumps; vaccines

Mesh:

Substances:

Year:  2017        PMID: 28490424      PMCID: PMC5498725          DOI: 10.1128/CVI.00034-17

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  85 in total

1.  Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.

Authors:  J M MacLennan; F Shackley; P T Heath; J J Deeks; C Flamank; M Herbert; H Griffiths; E Hatzmann; C Goilav; E R Moxon
Journal:  JAMA       Date:  2000-06-07       Impact factor: 56.272

2.  Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.

Authors:  Joon Young Song; Hee Jin Cheong; In Sook Hwang; Won Suk Choi; Yu Mi Jo; Dae Won Park; Geum Joo Cho; Taik Gun Hwang; Woo Joo Kim
Journal:  Vaccine       Date:  2010-04-13       Impact factor: 3.641

3.  Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme.

Authors:  K Broliden; E R Abreu; M Arneborn; M Böttiger
Journal:  Vaccine       Date:  1998 Jan-Feb       Impact factor: 3.641

4.  Waning antibody levels and avidity: implications for MMR vaccine-induced protection.

Authors:  Mia Kontio; Sari Jokinen; Mikko Paunio; Heikki Peltola; Irja Davidkin
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

Review 5.  Vaccination to gain humoral immune memory.

Authors:  Jana Sarkander; Shintaro Hojyo; Koji Tokoyoda
Journal:  Clin Transl Immunology       Date:  2016-12-23

Review 6.  B cell responses to influenza infection and vaccination.

Authors:  Christopher Chiu; Ali H Ellebedy; Jens Wrammert; Rafi Ahmed
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

7.  Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010.

Authors:  Geoffrey C Buckle; Christa L Fischer Walker; Robert E Black
Journal:  J Glob Health       Date:  2012-06       Impact factor: 4.413

8.  The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.

Authors:  Michael T White; Philip Bejon; Ally Olotu; Jamie T Griffin; Eleanor M Riley; Kent E Kester; Christian F Ockenhouse; Azra C Ghani
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

9.  An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution.

Authors:  Claire S Waddington; Thomas C Darton; Claire Jones; Kathryn Haworth; Anna Peters; Tessa John; Ben A V Thompson; Simon A Kerridge; Robert A Kingsley; Liqing Zhou; Kathryn E Holt; Ly-Mee Yu; Stephen Lockhart; Jeremy J Farrar; Marcelo B Sztein; Gordon Dougan; Brian Angus; Myron M Levine; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2014-02-10       Impact factor: 9.079

Review 10.  The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza.

Authors:  Anthony DiPiazza; Katherine A Richards; Zackery A G Knowlden; Jennifer L Nayak; Andrea J Sant
Journal:  Front Immunol       Date:  2016-01-25       Impact factor: 7.561

View more
  20 in total

1.  Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China.

Authors:  Lei Zhang; Zhiguo Wang; Ying Hu; Xiuying Deng; Hongxiong Guo; Xiang Sun; Fenyang Tang; Minghao Zhou; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

2.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

3.  CD45RB Status of CD8+ T Cell Memory Defines T Cell Receptor Affinity and Persistence.

Authors:  Scott M Krummey; Anna B Morris; Jesica R Jacobs; Donald J McGuire; Satomi Ando; Katherine P Tong; Weiwen Zhang; Jennifer Robertson; Sara A Guasch; Koichi Araki; Christian P Larsen; Brian D Evavold; Haydn T Kissick; Mandy L Ford
Journal:  Cell Rep       Date:  2020-02-04       Impact factor: 9.423

4.  Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.

Authors:  Elitza S Theel; Marisa Sorenson; Crystal Rahman; Dane Granger; Andrew Vaughn; Laura Breeher
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

5.  Vaccine waning and mumps re-emergence in the United States.

Authors:  Joseph A Lewnard; Yonatan H Grad
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

6.  Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.

Authors:  David J Dowling; Soumik Barman; Alyson J Smith; Francesco Borriello; Danielle Chaney; Spencer E Brightman; Gandolina Melhem; Byron Brook; Manisha Menon; Dheeraj Soni; Simone Schüller; Karthik Siram; Etsuro Nanishi; Hélène G Bazin; David J Burkhart; Ofer Levy; Jay T Evans
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

Review 7.  Knowledge gaps persist and hinder progress in eliminating mumps.

Authors:  R Ramanathan; E A Voigt; R B Kennedy; G A Poland
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 4.169

8.  3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.

Authors:  Sudhir Pai Kasturi; Mohammed Ata Ur Rasheed; Colin Havenar-Daughton; Mathew Pham; Traci Legere; Zarpheen Jinnah Sher; Yevgeny Kovalenkov; Sanjeev Gumber; Jessica Y Huang; Raphael Gottardo; William Fulp; Alicia Sato; Sheetal Sawant; Sherry Stanfield-Oakley; Nicole Yates; Celia LaBranche; S Munir Alam; Georgia Tomaras; Guido Ferrari; David Montefiori; Jens Wrammert; Francois Villinger; Mark Tomai; John Vasilakos; Christopher B Fox; Steven G Reed; Barton F Haynes; Shane Crotty; Rafi Ahmed; Bali Pulendran
Journal:  Sci Immunol       Date:  2020-06-19

9.  High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.

Authors:  Xiang Sun; Fenyang Tang; Ying Hu; Xiuying Deng; Zhiguo Wang; Minghao Zhou; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

Review 10.  Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  F Heath Damron; Mariette Barbier; Purnima Dubey; Kathryn M Edwards; Xin-Xing Gu; Nicola P Klein; Kristina Lu; Kingston H G Mills; Marcela F Pasetti; Robert C Read; Pejman Rohani; Peter Sebo; Eric T Harvill
Journal:  J Immunol       Date:  2020-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.